Blue Trust Inc’s Regenxbio RGNX Stock Holding History

Blue Trust Inc’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-373	Closed	-$8K	–	2432
2023 Q1	$8K	Sell	373 -36	-9%	-$797	﹤0.01%	1669
2022 Q4	$11K	Buy	+409	New	+$9.25K	﹤0.01%	1516

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Blue Trust Inc's RGNX Position: Q2 2023 in Review

Blue Trust Inc sold out of Regenxbio (RGNX) in Q2 2023, closing a stake of 373 shares — an estimated $8K sold.

Blue Trust Inc first reported a position in RGNX in Q4 2022 and held it in 2 quarters. The position peaked at $11K in Q4 2022. 167 funds tracked by Wall St. Rank hold RGNX as of Q2 2023.

Blue Trust Inc reported no remaining Regenxbio position as of Q2 2023 after selling out during the quarter.
Blue Trust Inc sold 373 Regenxbio shares in Q2 2023, an estimated $8K.
Blue Trust Inc first reported a position in Regenxbio in Q4 2022 and held it in 2 quarters.
Blue Trust Inc's Regenxbio position peaked at $11K in Q4 2022.
167 funds tracked by Wall St. Rank held Regenxbio as of Q2 2023.

Based on Blue Trust Inc's 13F filing for Q2 2023, filed 14 Jul 2023.